- In April 2023, Elanco Animal Health introduced Draxxin, a once-daily injectable antibiotic targeting severe gram-negative bacterial infections. This product launch boosted Elanco’s injectable solutions portfolio and reinforced market growth by addressing rising demand for effective treatment options in livestock health
- In March 2023, Virbac announced the launch of Synulox, a broad-spectrum antibiotic formulated to treat multiple animal infections. This addition expanded Virbac’s antibiotic offerings and enhanced its market footprint, particularly in the segment focusing on multipurpose solutions for respiratory, urinary, and skin infections
- In February 2023, Boehringer Ingelheim GmbH introduced Clavamox, a combination antibiotic containing amoxicillin and clavulanic acid. This launch significantly contributed to the market by supporting the use of combination therapies, offering increased efficacy against resistant strains, and fulfilling the demand for advanced infection management tools
- In January 2023, Ceva Santé Animale rolled out Enrofloxacin, a broad-spectrum antibiotic effective against various infections in animals. The launch of Enrofloxacin added momentum to the market’s expansion by catering to the growing need for potent, single-agent solutions across companion and food-producing animal sectors
- In July 2020, Trianni Inc. (USA) and Zoetis (USA) initiated a collaboration aimed at developing transgenic monoclonal antibody platforms to innovate veterinary medications. This partnership seeks to leverage Trianni's expertise in antibody discovery and Zoetis's leadership in animal health solutions. The FDA recently approved Zoetis's acquisition of Marboquin (USA), marking a strategic move to bolster their portfolio and capabilities in the veterinary pharmaceutical sector
